JP2001518096A - アポトーシス性酵素を不活性化するためのニトロシル化 - Google Patents
アポトーシス性酵素を不活性化するためのニトロシル化Info
- Publication number
- JP2001518096A JP2001518096A JP54191598A JP54191598A JP2001518096A JP 2001518096 A JP2001518096 A JP 2001518096A JP 54191598 A JP54191598 A JP 54191598A JP 54191598 A JP54191598 A JP 54191598A JP 2001518096 A JP2001518096 A JP 2001518096A
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound
- disorders
- cell
- pseudo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.有効量のS-ニトロシル化化合物を哺乳動物に投与することによる、哺乳動物 におけるアポトーシス性の非神経細胞性および非眼性の細胞死または損傷を改善 させる方法。 2.S-ニトロシル化化合物がカスパーゼの酵素活性を低下させる、請求項1記載の 方法。 3.化合物が下記の化合物からなる群より選択される、請求項1記載の方法: ニトログリセリン、 ニトロプルシドナトリウム、 硝酸イソソルビド(イソルジル)、 S-ニトロソカプトプリル(SNOCAP)、 一酸化窒素結合性血清アルブミン(「SA-NO」)、 一酸化窒素結合性カテプシン(カテプシン-NO)、 NO結合性組織プラスミノゲンアクチベーター(tPA-NO)、 SIN-1(またはモルシドミン)陽イオン-ニトロシル複合体[Fe2+-ニトロシル 複合体を含む]、 ニコランジル、 S-ニトロソグルタチオン、 NOと結合したメナンチンなどのエナメル質誘導体、 S-ニトロソシステインを含むS-ニトロソチオール類、 キノン類(ピロロギノリンキノン(PQQ)、PQQのエステル誘導体またはユビキ ノンを含む)、 SIN-1などのシドノイミン類。 4.化合物が、下記の式で表されるNONOエート(NONOate)である、請求項1記載 の方法: X-[N(O)NO]- 式中、Xは、アミンならびにα-リポ酸(チオクト酸およびその光学異性体)、ジ ヒドロリポ酸塩、グルタチオン、アスコルビン酸塩、およびビタミンEなどのNO によって生じるものと類似した酸化カスケードを生じる試薬を含む任意の求核基 。 5.化合物がニトロキシル(NO-)生成性物質である、請求項1記載の方法。 6.化合物がピローティ酸、アンジェリ塩(Oxi-NO)、またはsulfi-NOである、 請求項5記載の方法。 7.化合物が、本明細書に参照として組み入れられるフェーリッシュ(Feelisch )およびスタムラー(Stamler)による[一酸化窒素研究法(Methods in Nitric O xide Research)、Wiley and Sons、Chichester、UK(1996)、pp71〜115]の第7 章に記載されたNO生成性化合物である、請求項1記載の方法。 8.哺乳動物が、以下の疾患からなる群より選択される少なくとも1つの医学的適 応症を特徴とするヒト患者である、請求項1記載の方法: 非神経細胞性または非眼性の酸化ストレス、リンパ球疾患を含む自己免疫疾患 、全身性エリテマトーデス(SLE)、慢性関節リウマチ(RA)、線維芽細胞(強 皮症)、造血障害、アテローム性動脈硬化、肝胆汁性疾患を含む細胞死に伴う胃 腸疾患、細胞媒介性細胞傷害、薬物および化学物質中毒、発癌、ウイルス性疾患 、AIDSに伴うT細胞欠乏、糸球体腎炎、嚢胞性腎疾患、尿細管損傷、心筋虚血ま たは梗塞、糖尿病性腎症、シャーガス病、多発性嚢胞腎、低細胞性末期腎疾患、 糖尿病に伴う腎疾患、シェーグレン症候群、劇症肝炎(B型およびC型肝炎)、赤 血球障害、赤血球増加症、サラセミア、葉酸、ビタミンB12、鉄の欠乏症、グル コース-6-リン酸デヒドロゲナーゼの異常、骨髄障害、脊髄形成異常、慢性炎症 性疾患、ならびに非神経学的および非眼科学的な低酸素症および虚血につながる 外傷。 9.偽カスパーゼ酵素を含む治療用組成物を患者に投与することを含む、アポト ーシスを特徴とする医学的適応症を治療する方法。 10.医学的適応症が、例えばNMDAおよび非NMDA受容体複合体を含むグルタミン酸 受容体の過度の刺激などの興奮毒性によって媒介される中枢神経系ニューロンの 損傷を特徴とする、請求項9記載の方法。 11.偽カスパーゼ酵素が配列QACRGを含む、請求項9記載の方法。 12.偽カスパーゼ酵素が配列IQACRGを含む、請求項11記載の方法。 13.偽カスパーゼ酵素がIQACRGである、請求項12記載の方法。 14.偽カスパーゼ酵素が、血液脳関門および/または細胞膜の透過を増強させる 移行成分を含む治療用組成物中に包含される、請求項9〜13のいずれか一項記載 の 方法。 15.移行成分がアンテナペディア蛋白質であって、該アンテナペディア蛋白質が 偽カスパーゼ酵素と結合している、請求項14記載の方法。 16.治療用組成物が透過性を高めるためのリポソームを含む、請求項9〜13のい ずれか一項記載の方法。 17.医学的適応症が、パーキンソン病、アルツハイマー病、筋萎縮性側索硬化症 、神経系の自己免疫性炎症、多発性硬化症、脱髄疾患、自己免疫性脳脊髄炎、て んかん重積持続状態およびその他の発作性疾患、神経性機械的外傷、神経細胞性 低酸素症、低血糖症または虚血、ハンチントン病、AIDS痴呆、脳卒中、神経障害 性疼痛、代謝異常(ホモシスチン血症を含む)、トゥレット症候群、ならびに薬 物の嗜癖、耐性、離脱、または依存症である、請求項9記載の方法。 18.医学的適応症が、非神経細胞性または非眼科性酸化ストレス、リンパ球疾患 を含む自己免疫疾患、全身性エリテマトーデス(SLE)、慢性関節リウマチ(RA )、線維芽細胞(強皮症)、造血障害、アテローム性動脈硬化、肝胆汁性疾患を 含む細胞死に伴う胃腸疾患、細胞媒介性細胞傷害、薬物および化学物質中毒、発 癌、ウイルス性疾患、AIDSに伴うT細胞欠乏、糸球体腎炎、嚢胞性腎疾患、尿細 管損傷、心筋梗塞、糖尿病性腎症、シャーガス病、多発性嚢胞腎、低細胞性末期 腎疾患、糖尿病に伴う腎疾患、シェーグレン症候群、劇症肝炎(B型およびC型肝 炎)、赤血球障害、赤血球増加症、サラセミア、葉酸、ビタミンB12、鉄の欠乏 症、グルコース-6-リン酸デヒドロゲナーゼの異常、骨髄障害、脊髄形成異常、 慢性炎症性疾患、ならびに非神経学的および非眼科学的な低酸素症および虚血に つながる外傷である、請求項9記載の方法。 19.偽カスパーゼ酵素を含む組成物を硝子体内に投与することを含む、眼科学的 疾患を特徴とする患者を治療する方法。 20.治療用組成物がリポソームを含む、請求項17または請求項19記載の方法。 21.治療用組成物が、偽カスパーゼ酵素と結合したアンテナペディア蛋白質を含 む、請求項17または請求項19記載の方法。 22.眼科学的疾患が緑内障である、請求項21記載の方法。 23.眼科学的適応症が視神経障害である、請求項19記載の方法。 24.治療用組成物がリポソーム中に存在する状態で投与される、請求項21記載の 方法。 25.患者にS-ニトロシル化化合物を投与することをさらに含む、請求項9記載の 方法。 26.有効量のS-ニトロシル化化合物を患者に投与することによって、患者におけ る薬物離脱症状、薬物耐性または薬物嗜癖を治療する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4214497P | 1997-03-31 | 1997-03-31 | |
US60/042,144 | 1997-03-31 | ||
PCT/US1998/006287 WO1998043621A1 (en) | 1997-03-31 | 1998-03-31 | Nitrosylation to inactivate apoptotic enzymes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009111141A Division JP2009221206A (ja) | 1997-03-31 | 2009-04-30 | アポトーシス性酵素を不活性化するためのニトロシル化 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001518096A true JP2001518096A (ja) | 2001-10-09 |
JP4777489B2 JP4777489B2 (ja) | 2011-09-21 |
Family
ID=21920265
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54191598A Expired - Fee Related JP4777489B2 (ja) | 1997-03-31 | 1998-03-31 | アポトーシス性酵素を不活性化するためのニトロシル化 |
JP2009111141A Pending JP2009221206A (ja) | 1997-03-31 | 2009-04-30 | アポトーシス性酵素を不活性化するためのニトロシル化 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009111141A Pending JP2009221206A (ja) | 1997-03-31 | 2009-04-30 | アポトーシス性酵素を不活性化するためのニトロシル化 |
Country Status (4)
Country | Link |
---|---|
US (3) | US20020106404A1 (ja) |
EP (1) | EP0979073A4 (ja) |
JP (2) | JP4777489B2 (ja) |
WO (1) | WO1998043621A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006503901A (ja) * | 2002-10-25 | 2006-02-02 | デューク・ユニバーシティー | レセプターの脱感作の予防 |
WO2008035686A1 (fr) * | 2006-09-19 | 2008-03-27 | Kyowa Hakko Bio Co., Ltd. | Agent pour améliorer la résistance à l'insuline |
JP2010248203A (ja) * | 1998-10-26 | 2010-11-04 | Research Foundation Of State Univ Of New York | リポ酸誘導体および疾患の治療におけるそれら誘導体の使用 |
JP2013518866A (ja) * | 2010-02-05 | 2013-05-23 | アイエスピー・インヴェストメンツ・インコーポレイテッド | 新規カスパーゼ−14活性化ペプチドおよびそれを含む組成物 |
JP2019503401A (ja) * | 2016-02-04 | 2019-02-07 | 南京舒鵬生物科技有限公司Nanjing Shupeng Lifescience Co., Ltd | ピロロキノリンキノン、その誘導体及び/又は塩の乾燥症候群における使用ならびに医薬組成物 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6310052B1 (en) | 1996-06-04 | 2001-10-30 | Queen's University At Kingston | Nitrate esters and their use for neurological conditions |
WO2001070199A1 (en) * | 2000-03-20 | 2001-09-27 | Novovascular, Inc. | Matrices containing nitric oxide donors and reducing agents and their use |
HUP0002628A2 (en) * | 2000-07-14 | 2002-06-29 | Keri Pharma Kft | Pharmaceutical combinations for treating diabetes |
KR100380393B1 (ko) * | 2000-10-09 | 2003-04-16 | 주식회사 씨트리 | 일산화질소-매개 아폽토시스 조절제 및 이를 이용한일산화질소-매개 아폽토시스 조절방법 |
US7432301B2 (en) * | 2001-08-20 | 2008-10-07 | University Of Virginia Patent Foundation | Use of S-nitrosothiol signaling to treat disordered control of breathing |
EP1421952A4 (en) * | 2001-08-22 | 2005-02-16 | Mitsuhiro Yokota | MYOKARDZELL-APOPTOSIS INHIBITORS |
US7276514B2 (en) | 2002-05-15 | 2007-10-02 | Charitable Leadership Foundation - Medical Technology Acceleration Program | Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof |
WO2003099282A1 (en) * | 2002-05-24 | 2003-12-04 | Children's Medical Center Corporation | White matter neuroprotectant pyrroloquinoline quinone compounds and methods of use thereof |
US20040038947A1 (en) | 2002-06-14 | 2004-02-26 | The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services | Method of treating ischemia/reperfusion injury with nitroxyl donors |
US6936639B2 (en) | 2002-08-21 | 2005-08-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroxyl progenitors in the treatment of heart failure |
US20050163873A1 (en) * | 2004-01-14 | 2005-07-28 | Robert Ritch | Methods and formulations for treating glaucoma |
JP2007536256A (ja) * | 2004-05-05 | 2007-12-13 | シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド | 心臓損傷の処置のためのピロロキノリンキノン薬およびその使用方法 |
WO2007116458A1 (ja) * | 2006-03-30 | 2007-10-18 | Tohru Hasegawa | 神経変性疾患治療薬 |
EP2068879A2 (en) * | 2006-05-02 | 2009-06-17 | Medical Technology Acceleration Program, Inc. | Pyrroloquinoline quinone drugs and methods of use thereof |
JP4935242B2 (ja) | 2006-08-24 | 2012-05-23 | ニプロ株式会社 | 脂肪酸を含有するs−ニトロソタンパク質とその製法 |
JP5791064B2 (ja) * | 2009-07-17 | 2015-10-07 | エア・ウォーター株式会社 | 医薬用組成物 |
AU2010328230B2 (en) | 2009-12-07 | 2016-06-02 | Cardioxyl Pharmaceuticals, Inc. | Bis-acylated hydroxylamine derivatives |
US20140127288A1 (en) * | 2011-05-17 | 2014-05-08 | Mitsubishi Gas Chemical Company, Inc. | Liposome containing pyrroloquinoline quinone and sugar |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5091391A (en) * | 1990-08-16 | 1992-02-25 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of resisting neurodegenerative disorders |
US5455279A (en) * | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
DK1023905T3 (da) * | 1991-11-14 | 2005-05-30 | Brigham & Womens Hospital | Farmaceutisk præparat indeholdende S-nitroso-immunoglobuliner og anvendelse deraf |
AU3237193A (en) * | 1991-12-11 | 1993-07-19 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
WO1993020806A1 (en) * | 1992-04-13 | 1993-10-28 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of nitric oxide/nucleophile complexes for the treatment of cancer |
AU7972294A (en) * | 1993-10-07 | 1995-05-01 | Entremed, Inc | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
DK0726265T3 (da) * | 1995-02-08 | 2001-10-22 | Novartis Ag | 10-Aminoaliphatyl-dibenz[b,f]oxepiner med antineurodegenerativ virkning |
US5856169A (en) * | 1995-02-21 | 1999-01-05 | Thomas Jefferson University | Isoforms of human interleukin-1β converting enzyme and methods of using the same |
US6750196B1 (en) * | 1995-03-27 | 2004-06-15 | Acorda Therapeutics | Methods of treating disorders of the eye |
US5674734A (en) * | 1995-05-18 | 1997-10-07 | President And Fellows Of Harvard College | Cell death protein |
US5672500A (en) * | 1995-05-18 | 1997-09-30 | Thomas Jefferson University | Mch2, an apoptotic cysteine protease, and compositions for making and methods of using the same |
JPH08310955A (ja) * | 1995-05-19 | 1996-11-26 | Santen Pharmaceut Co Ltd | 網膜疾患治療剤 |
US6197745B1 (en) * | 1995-09-15 | 2001-03-06 | Duke University | Methods for producing nitrosated hemoglobins and therapeutic uses therefor |
AU7529796A (en) * | 1995-11-13 | 1997-06-05 | Brigham And Women's Hospital | S-nitroso-hemoglobin and therapeutic uses thereof |
US6635738B2 (en) * | 1996-03-04 | 2003-10-21 | The Trustees Of Columbia University In The City Of New York | Compounds which prevent neuronal cell death and uses thereof |
DE19648185A1 (de) * | 1996-11-21 | 1998-05-28 | Asea Brown Boveri | Geschweisster Rotor einer Strömungsmaschine |
US5929042A (en) * | 1997-03-03 | 1999-07-27 | The Trustees Of Columbia University In The City Of New York | Antisense compounds which prevent cell death and uses thereof |
US5840979A (en) * | 1997-07-14 | 1998-11-24 | University Of Saskatchewan | Aliphatic propargylamines as cellular rescue agents |
US7143021B1 (en) * | 2000-10-03 | 2006-11-28 | Cadence Design Systems, Inc. | Systems and methods for efficiently simulating analog behavior of designs having hierarchical structure |
FR2825748B1 (fr) * | 2001-06-07 | 2003-11-07 | Snecma Moteurs | Agencement de rotor de turbomachine a deux disques aubages separes par une entretoise |
DE10355738A1 (de) * | 2003-11-28 | 2005-06-16 | Alstom Technology Ltd | Rotor für eine Turbine |
-
1998
- 1998-03-31 WO PCT/US1998/006287 patent/WO1998043621A1/en active Application Filing
- 1998-03-31 EP EP98913316A patent/EP0979073A4/en not_active Withdrawn
- 1998-03-31 JP JP54191598A patent/JP4777489B2/ja not_active Expired - Fee Related
-
2002
- 2002-01-22 US US10/055,417 patent/US20020106404A1/en not_active Abandoned
-
2004
- 2004-05-05 US US10/839,434 patent/US20040265369A1/en not_active Abandoned
-
2006
- 2006-11-08 US US11/594,565 patent/US20070218121A1/en not_active Abandoned
-
2009
- 2009-04-30 JP JP2009111141A patent/JP2009221206A/ja active Pending
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010248203A (ja) * | 1998-10-26 | 2010-11-04 | Research Foundation Of State Univ Of New York | リポ酸誘導体および疾患の治療におけるそれら誘導体の使用 |
JP2006503901A (ja) * | 2002-10-25 | 2006-02-02 | デューク・ユニバーシティー | レセプターの脱感作の予防 |
JP4705783B2 (ja) * | 2002-10-25 | 2011-06-22 | デューク ユニバーシティ | レセプターの脱感作の予防 |
WO2008035686A1 (fr) * | 2006-09-19 | 2008-03-27 | Kyowa Hakko Bio Co., Ltd. | Agent pour améliorer la résistance à l'insuline |
US8097635B2 (en) | 2006-09-19 | 2012-01-17 | Kyowa Hakko Bio Co., Ltd. | Insulin resistance improving agent |
JP2013518866A (ja) * | 2010-02-05 | 2013-05-23 | アイエスピー・インヴェストメンツ・インコーポレイテッド | 新規カスパーゼ−14活性化ペプチドおよびそれを含む組成物 |
JP2019503401A (ja) * | 2016-02-04 | 2019-02-07 | 南京舒鵬生物科技有限公司Nanjing Shupeng Lifescience Co., Ltd | ピロロキノリンキノン、その誘導体及び/又は塩の乾燥症候群における使用ならびに医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20020106404A1 (en) | 2002-08-08 |
EP0979073A1 (en) | 2000-02-16 |
JP2009221206A (ja) | 2009-10-01 |
EP0979073A4 (en) | 2004-04-07 |
WO1998043621A1 (en) | 1998-10-08 |
US20070218121A1 (en) | 2007-09-20 |
US20040265369A1 (en) | 2004-12-30 |
JP4777489B2 (ja) | 2011-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001518096A (ja) | アポトーシス性酵素を不活性化するためのニトロシル化 | |
EP1937286B1 (en) | Compositions comprising dimethyl sulfoxide (dmso) | |
US6395747B1 (en) | Remedies for multiple sclerosis | |
US5948800A (en) | Preventive or therapeutic drug for Alzheimer's disease | |
US5604199A (en) | Method of treating fibrosis in skeletal muscle tissue | |
JPH04275231A (ja) | 事故結果として多外傷を有する危険な患者に於て、臓器拒絶の予防及び(又は)処置に、スーパーオキシドジスムターゼを使用する方法 | |
EP0715850B1 (en) | Use of proline and/or derivatives as an antihepatitis agent | |
DE60113078T2 (de) | VERWENDUNG VON MnTBAP ZUR BEHANDLUNG VON HEPATISCHER INSUFFIZIENZ | |
US20100143321A1 (en) | Therapeutic composition for interstitual pneumonia | |
EP1061938B1 (en) | Oral compositions at low dosage of cytotoxic proteins | |
CN110538172B (zh) | 铁死亡抑制剂在制备治疗金诺芬肝毒性的药物中的应用 | |
AU2014257131B2 (en) | Methods and compositions for treating diseases | |
Woolley et al. | A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma | |
US6596755B2 (en) | Oral formulation of methylglyoxal and its imino acid conjugates for human use | |
US20220257536A1 (en) | Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions | |
EP4282411A1 (en) | Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury | |
JP2003527414A (ja) | C型肝炎を治療するための薬剤 | |
AU2022401717A1 (en) | Combinatorial therapeutic approach for friedreich's ataxia | |
JPH0621062B2 (ja) | 肝障害抑制剤 | |
US20050176812A1 (en) | Method of treating cancer | |
US20050192228A1 (en) | Tripeptide derivatives for the treatment of neurodegenerative diseases | |
JPH08208472A (ja) | 抗肝炎剤 | |
WO2004032972A1 (en) | An oral formulation of methylglyoxal and its imino acid conjugates for human use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050330 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050608 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090202 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090316 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090225 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090302 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090413 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090403 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090430 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100309 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100602 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100712 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100908 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110607 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110630 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140708 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |